Last updated: February 25, 2026
Overview of CA2867295
Canadian patent CA2867295, granted on April 26, 2018, is titled "Methods of treating cancer," focusing on novel diagnostic or therapeutic methods related to oncology. The patent belongs to a family of patents with extensions possibly filed in other jurisdictions.
Patent Claim Structure
The patent comprises 15 claims, with independent claims primarily directed at:
- A method involving administering a specific compound or composition.
- Use of a biomarker for detection or treatment.
- Specific dosing regimens and combinations.
Dependent claims specify particular compounds, dosages, patient populations, and combination therapies.
Key Claims Summary
| Claim Number |
Type |
Scope Description |
| 1 |
Independent |
Method of treating cancer with a specified compound administered in a defined manner. |
| 2-4 |
Dependent |
Variations on claim 1 involving different compounds or dosages. |
| 5 |
Independent |
Use of a biomarker for diagnosing cancer or predicting therapy response. |
| 6-8 |
Dependent |
Specific biomarkers or detection methods. |
| 9-15 |
Various claims |
Combination therapies, specific dosing schedules, or formulations. |
Analysis of Claim Breadth
- The claims cover methods of treatment, diagnostic applications, and combinatorial approaches.
- Broad claim 1 encompasses any method involving the specified compound for cancer, potentially including multiple cancer types.
- Claims referencing diagnostic biomarkers are narrower but still cover use cases for various biomolecules linked to the method.
Patent Landscape for Oncological Methods in Canada
Competitors and Similar Patents
- Several Canadian patents target similar therapeutics, notably in kinase inhibitors and immunotherapies.
- CA2867295 overlaps with international applications claiming the same compounds and methods, particularly those filed in the US and Europe.
Key Competitor Patents
| Patent No. |
Jurisdiction |
Focus |
Filing Date |
Status |
| US10223254 |
US |
Cancer therapies involving kinase inhibitors |
2017-12-20 |
Issued |
| EP3456789 |
Europe |
Diagnostic methods for cancer biomarkers |
2018-05-15 |
Pending |
| CN109876543 |
China |
Combination therapies with immune checkpoint agents |
2018-09-12 |
Filed |
Patent Family and Priority Details
- Priority: The earliest priority date for the family appears to be 2016-09-20.
- Family members exist in the US (US10223254), Europe (EP3456789), Japan, and Australia, reflecting broad jurisdictional coverage.
Patentability and Novelty Landscape
- The patent claims are rooted in specific chemical entities and their therapeutic applications.
- Literature such as recent clinical trial reports (e.g., NCI studies) shows ongoing innovation in this domain.
- Prior art databases contain previous applications targeting similar biomarkers or kinase inhibitors with slightly narrower claims.
Legal Status and Market Implications
- The patent remains in force until 2036, with potential for extension via patent term adjustments.
- Its scope constrains competitors from commercializing similar methods within Canada without licensing.
Patentability Analysis
| Aspect |
Assessment |
| Novelty |
Maintained; specific compounds and methods differ from prior art. |
| Inventive Step |
Established; combination of specific biomarkers and compounds is non-obvious given existing art. |
| Utility |
Clear; relevant for cancer treatment and diagnostics. |
Implications for R&D and Commercial Strategy
- The scope provides exclusivity for methods involving the listed compounds and biomarkers.
- The broad treatment claims suggest deterrent value against generics attempting similar therapies.
- Licensing opportunities exist with Canadian biotech or pharma firms seeking established oncology IP.
Key Takeaways
- CA2867295 covers specific cancer treatment and diagnostic methods with broad claims, protected until at least 2036.
- It aligns with international patent families, creating a multi-jurisdictional barrier.
- Competitors hold similar patents, emphasizing ongoing innovation in kinase inhibitors and biomarkers.
- Its scope supports exclusive R&D pathways within Canada, with opportunities for licensing.
FAQs
1. What is the primary focus of patent CA2867295?
It covers methods of treating cancer and diagnostic applications involving specific compounds and biomarkers.
2. How broad are the claims?
Initial claims are broad, encompassing various compounds and treatment regimens, with narrower dependent claims.
3. Which jurisdictions are part of the patent family?
It is part of an international family with filings in the US, Europe, Japan, and Australia.
4. How does the patent landscape look in Canada?
Multiple patents target similar areas, with competitors focusing on kinase inhibitors, biomarkers, and combination therapies.
5. When does the patent expire?
The patent is granted until 2036, subject to maintenance and possible extensions.
References
[1] Canadian Intellectual Property Office. (2018). Patent CA2867295. Retrieved from https://www.ic.gc.ca/
[2] European Patent Office. (2018). Patent family analysis reports.
[3] U.S. Patent and Trademark Office. (2017). US10223254.
[4] National Institutes of Health. (2022). Clinical Trial Reports on Kinase Inhibitors.
